vTv Therapeutics’ (VTVT) Buy Rating Reaffirmed at BTIG Research

vTv Therapeutics (NASDAQ:VTVT)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports. They currently have a $57.00 target price on the biotechnology company’s stock. BTIG Research’s price target would suggest a potential upside of 101.91% from the company’s previous close.

A number of other research firms have also recently commented on VTVT. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 2nd. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Zacks Research raised shares of vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. HC Wainwright reduced their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, Weiss Ratings cut shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.83.

vTv Therapeutics Stock Down 7.3%

NASDAQ:VTVT opened at $28.23 on Wednesday. vTv Therapeutics has a 52 week low of $19.50 and a 52 week high of $44.00. The stock has a market capitalization of $111.23 million, a PE ratio of -26.63 and a beta of 0.21. The stock’s 50-day moving average price is $31.90 and its 200-day moving average price is $33.55.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Sell-side analysts expect that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.

About vTv Therapeutics

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.